AMNOG Report 2025: Overly complex cost containment achieves nothing
Rampant supplementary contributions make the question of how to rein in the innovation component that drives pharmaceutical spending more urgent. The new AMNOG report from the DAK advocates simple yet effective solutions.
Arzte zeitung
